Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-LN phase 3 trial of ianalumab plus standard of care in active lupus nephritis
CTR20221011Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ianalumab in lupus nephritis (LN), sponsored by Novartis. Started Oct 2022; status: active.
02
Drugs
ianalumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20221011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221011.